The protein tyrosine phosphatase, SHP-1, is a negative regulator of proinflammatory signaling and autoimmune disease. We have previously reported reduced SHP-1 expression in peripheral blood leukocytes of subjects with multiple sclerosis (MS). Recent evidence indicates that virus-induced DNA methylation of the SHP-1 promoter is responsible for aberrant silencing of SHP-1 expression and function in hematopoietic cells that might relate to inflammatory diseases. In the present study, bisulfite sequencing of the SHP-1 promoter demonstrated that over a third of MS subjects had abnormally high promoter methylation. As SHP-1 is deficient in MS leukocytes and SHP-1-regulated proinflammatory genes are correspondingly upregulated, we propose that increased SHP-1 promoter methylation may relate in part to decreased SHP-1 expression and increased leukocytemediated inflammation in MS.
Introduction
Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system (Kornek and Lassmann, 2003) . A recent analysis of multiple sclerosis (MS) patient tissue discovered that activated transcription factors, such as NF-κB and STATs, are present in MS lesions and peripheral blood mononuclear cells (PBMC) of MS patients (Gobin et al., 2001; Frisullo et al., 2006; Christophi et al., 2008 Christophi et al., , 2012 , suggesting that altered regulation of cytokine signaling that occurs in MS patients may be responsible for promoting expression of proinflammatory genes and inflammatory demyelination in MS lesions.
SHP-1, a protein tyrosine phosphatase, contains two SH2 domains and functions as a negative regulator of cytokine signaling through both NF-κB and STATs (David et al., 1995; Jiao et al., 1996) . When motheaten mice (me/me), which genetically lack SHP-1 gene expression, are subjected to either virus-induced or autoantigen-induced demyelinating diseases, an increased level of inflammatory demyelination relative to that seen in wild type mice is observed (Deng et al., 2002; Massa et al., 2002) . Abnormally low levels of SHP-1 in mice (hypomorphic mutations) also cause increased susceptibility to autoimmune and innate inflammatory disease (Croker et al., 2008 (Croker et al., , 2011 . Moreover, reduced SHP-1 in lymphocytes has been related to human lymphoproliferative diseases (Zhang et al., 2000; Oka et al., 2001; Oka et al., 2002; Koyama et al., 2003) . These results indicate that SHP-1 plays an important role in lymphocyte activation and proliferation, which may be important to inflammatory demyelinating immune reactions in white matter observed in MS.
We and others previously described that the anti-inflammatory gene SHP-1 is reduced in PBMC of MS compared to normal subjects both at the mRNA and protein levels which may relate to increased inflammatory activity of these cells in the CNS. Further analysis indicated that both lymphocytes and myeloid cells of MS patients have lower amounts of SHP-1 protein (Feng et al., 2002; Christophi et al., 2008) . Moreover, decreased SHP-1 correlated with specific repression of promoter 2 (hematopoietic specific) relative to promoter 1 (epithelial specific) (Tsui et al., 2002 ) transcripts (Christophi et al., 2008a , 2009a . Therefore, reduced promoter 2 transcriptional activity may be responsible for reduced expression of SHP-1 in PBMC in MS.
Several studies have described the reduction of SHP-1 expression in various inflammatory and lymphoproliferative disorders. In the latter, DNA methylation within promoter 2 of the SHP-1 gene was responsible for a strong reduction of SHP-1 mRNA and protein (Howell et al., 2000; Oka et al., 2001; Oka et al., 2002; Koyama et al., 2003; Ruchusatsawat et al., 2006; Nakase et al., 2009 ). In the present study, we addressed the question of whether similar methylation Journal of Neuroimmunology 246 (2012) [51] [52] [53] [54] [55] [56] [57] 
